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Novel anti-thrombotic agent for 
modulation of protein disulfide 
isomerase family member ERp57 
for prophylactic therapy
Guozhen Cui1,2,*, Luchen Shan3,4,*, Lin Guo3, Ivan Keung Chu5, Guohui Li5, Quan Quan3, 
Yun Zhao5, Cheong Meng Chong1, Zaijun Zhang3, Pei Yu3, Maggie Pui Man Hoi1, Yewei Sun3, 
Yuqiang Wang3 & Simon MingYuen Lee1
Protein disulfide isomerase (PDI) family members including PDI and ERp57 emerge as novel targets 
for anti-thrombotic treatments, but chemical agents with selectivity remain to be explored. We 
previously reported a novel derivative of danshensu (DSS), known as ADTM, displayed strong 
cardioprotective effects against oxidative stress-induced cellular injury in vitro and acute myocardial 
infarct in vivo. Herein, using chemical proteomics approach, we identified ERp57 as a major target 
of ADTM. ADTM displayed potent inhibitory effects on the redox activity of ERp57, inhibited the 
adenosine diphosphate (ADP)-induced expressions of P-selectin and α IIbβ 3 integrin, and disrupted 
the interaction between ERp57 and α IIbβ 3. In addition, ADTM inhibited both arachidonic acid (AA)-
induced and ADP-induced platelet aggregation in vitro. Furthermore, ADTM significantly inhibited rat 
platelet aggregation and thrombus formation in vivo. Taken together, ADTM represents a promising 
candidate for anti-thrombotic therapy targeting ERp57.
Cardiovascular diseases (CVDs) remain the leading causes of morbidity and mortality globally. The 
underlying causes of CVDs are complex and multi-factorial involving many risk factors such as abnor-
mal blood lipid, high blood cholesterol levels, overweight and sedentary lifestyle1,2. In particular, platelet 
dysfunction and aberrant thrombogenesis (thrombus formation) are final underlying pathophysiological 
processes in the development and progression in CVDs including atherosclerosis, thrombotic compli-
cations, stroke and myocardial infarction3. Current anti-platelet agents such as aspirin and clopidogrel 
are effective at decreasing platelet activation and subsequent risk of atherothrombotic disease, but these 
agents irreversibly inhibit platelet activation and lead to risks of unwanted hemorrhages4,5. Furthermore, 
the multi-factorial nature of CVDs urges us to look for versatile pharmacological agents with fewer side 
effects.
We have reported previously that a novel cardioprotective compound known as ADTM was synthe-
sized in our laboratory by conjugating two well-known active ingredients, DSS and tetramethylpyrazine 
(TMP), which are present in Chinese medicinal plants, danshen (Salvia miltiorrhizae) and chuanx-
iong (Ligustium wallichii Franch)6. ADTM displayed strong cardioprotective effects against oxidative 
stress-induced cellular injury and acute ischemic myocardial infarct in rat, partly through activation of 
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the anti-oxidative stress Nrf2/heme oxygenase-1 (HO-1) pathway7. Several registered pharmaceutical 
products containing danshen and/or chuanxiong such as “Danshen Dripping Pill” and “Guanxinning 
Injection” have been widely used in China to treat CVDs. The “Danshen Dripping Pill” was approved 
by the US Food and Drug Administration (FDA) to undergo Phase III clinical trials in the treatment of 
CVDs8. Clinical studies indicated that these pharmaceutical products are effective in treating angina pec-
toris, a symptom of ischemic heart disease9. It is believed that active ingredients in danshen and chuanx-
iong induce beneficial therapeutic effects by the promotion of better blood circulation10,11. Therefore, we 
postulated that ADTM might also display anti-platelet and anti-thrombotic properties.
Several members of the protein disulfide isomerases have been shown as important players in the 
regulation of platelet functions and thrombus formation including PDI, ERp72, ERp57 and ERp512–
14. However, which member in the family represents the best anti-thrombotic drug target is largely 
unknown13. The prototypical member PDI is a multifunctional redox chaperone protein that plays crit-
ical roles in a variety of diseases including platelet aggregation and thrombus formation in vivo and in 
vitro15–17. More recently, it is shown that blood platelets also secreted ERp57 (also known as GRP58 
and PDIA3) in response to vascular injury to trigger platelet activation and aggregation and emerges 
as a novel target for anti-platelet aggregation and anti-thrombosis18–20. Human ERp57 has 32% amino 
acid sequence homology with PDI, and exhibits 40% identity with the a-b-b´-a´domains of ERp7221. 
However, selective chemical agents for ERp57 are not yet available.
In this study, we further identified the drug target of ADTM as ERp57 by using a chemical proteomics 
approach analyzing liquid chromatography linked to tandem mass spectrometry (LC-MS/MS) profile of 
pull-down proteins bound to a biotinylated-ADTM analogue (BAA). The anti-platelet aggregation and 
anti-thrombosis activities of ADTM were determined both in vitro and in vivo. The results provided 
promising evidences for the potential of developing novel anti-CVD and anti-thrombotic agents with 
selectivity at the protein disulfide isomerases by using ADTM.
Results
Protein disulfide isomerases are identified as targets of ADTM by chemical proteomics. In 
order to isolate the protein targets that bound to ADTM, a biotin-conjugated ADTM analogue (BAA, 
Fig.  1) was designed and synthesized in our laboratory as described in Supplementary Methods 
(Supplemental Fig. 3). BAA (300 μ M) was incubated with rat blood platelet lysates and the BAA-protein 
complexes were pulled down with NeutrAvidin-agarose followed by protein profiling using LC-MS/MS. 
It was observed that BAA could bind to various proteins involved in platelet function, including glyco-
protein 5 (a potential marker of thrombotic platelet activation22,23), superoxide dismutase and xanthine 
oxidase (regulators of vascular redox signaling24). In particular, four platelet aggregation-associated pro-
teins were identified with > 95% protein identification probability (Supplementary Table S1), including 
ERp72, ERp57 ERp5 and PDI, which are glycoprotein-specific members of the PDI family related to 
platelet function and redox homeostasis25,26. We confirmed the identity of the pulled-down proteins 
as ERp72, ERp57 and ERp5 with their respective antibodies by using immunoblot analysis (Fig.  2b). 
Furthermore, the specificity of the binding between BAA and these targets (ERp72, ERp57 and ERp5) 
could be demonstrated by the competition with untagged ADTM in excess (Fig.  2a). The molecular 
docking analysis demonstrated that the free binding energy to the active cavity of ERp57 (PDB: 3F8U) 
is − 6.5 kcal/mol. ADTM may form hydrogen bonds with side chains of ARG47, ILE453 and PHE450, 
respectively, in the catalytic center (CYS406/CYS409) of ERp57 (Supplemental Fig. 2). ERp72, ERp57, 
ERp5 and PDI are identified as important new targets in redox homeostasis of blood platelet aggrega-
tion12, therefore we further evaluated the effects of ADTM on the reducing activities of the PDI family 
members. As shown in Fig. 2c, ADTM exhibited potent inhibition on the redox activity of ERp57 in a 
concentration-dependent manner (IC50 = 100 to 300 μ M). ADTM inhibited the activities of ERp72, ERp5 
and PDI to a much lesser extent (18%, 38% and 30% of inhibition at 300 μ M, respectively), displaying 
differential inhibitory activity at ERp57 (order of potency as follows: ERp57 > ERp5 > PDI > ERp72). 
Figure 1. Chemical structures of DSS, TMP, ADTM, and BAA.
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ERp57 inhibition by ADTM was irreversible after dilution of the ERp57-ADTM complex (Supplemental 
Figure 1), indicating that ADTM may covalently bind ERp57.
ADTM inhibits platelet aggregation in vitro. It was observed that ADTM exhibited concentra-
tion-dependent inhibition on ADP-induced platelet aggregation (Fig. 3a) as well as AA-induced platelet 
aggregation (Fig. 3b) in vitro and its effects were comparable to first-line clinical anti-platelet drugs, aspi-
rin and clopidogrel. The parent compounds DSS and TMP, alone or in combination, could only inhibit 
AA-induced platelet aggregation but not ADP-induced platelet aggregation. These results demonstrated 
that ADTM exhibited broad-spectrum anti-platelet activities.
ADTM inhibits the expression of P-selectin. To further investigate the underlying mechanism 
of ADTM anti-platelet activity, we examined the effect of ADTM on the expression of P-selectin (also 
Figure 2. Target validation and the inhibition of PDI members by ADTM. (a) Schematics of the target 
validation. (b) Proteins isolated from rat platelets were pretreated with DMSO or excess amount of untagged 
ADTM for 2 h, followed by treatment with BAA for another 2 h, and compound-protein-complexes were 
enriched with NeutrAvidin-agarose resin. The precipitates were detected by immunoblot for indicated 
proteins of PDI family. (c) ADTM selectively inhibits ERp57. The recombinant PDI, ERp57 and ERp72 
proteins were incubated with different concentrations of ADTM for 100 min, and its catalytic activity was 
determined in insulin reduction assay.
Figure 3. Inhibitory effects of ADTM on ADP-and AA-induced platelet aggregation in vitro. Platelets 
were pretreated with or without the indicated concentrations of the tested compounds, ADTM (1–100 μ M), 
DSS (100 μ M), TMP (100 μ M), aspirin (1–100 μ M) and clopidogrel (1–100 μ M) for 5 min at 37 °C and the 
percentage (%) of platelet aggregation inhibition normalized to DMSO treated samples (vehicle control) was 
determined as described in Materials and Methods. The platelets were stimulated with ADP (a), and AA (b). 
Data are expressed as mean ± SD, *P < 0.01 compared with the 100 μ M DSS group. #P < 0.01 compared with 
the 100 μ M TMP group, &P < 0.01 compared with the 100 μ M DSS + TMP group, n ≥ 3/group. D = DSS, 
T = TMP, ASA = aspirin, clop = clopidogrel.
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known as CD62P), which is an adhesion molecule expressed on the surface of platelet and is a critical 
marker of platelet activation, by using immunoreactivity and flow cytometry analysis. We observed that 
ADTM concentration-dependently inhibited ADP-induced expression of P-selectin and attenuated the 
expression of P-selectin by more than 65% at 100 μ M (Fig. 4a and 4b).
ADTM inhibits activation of αIIbβ3 and disrupted ERp57/αIIbβ3 interaction. Recently, ERp57 
has been reported to directly interact with α IIbβ 3 integrin and regulate its function in platelet aggrega-
tion20. In line with this, we observed that ADTM could modulate α IIbβ 3 and concentration-dependently 
inhibited ADP-induced α IIbβ 3 activation, by using flow cytometry analysis with PAC-1, a monoclonal 
antibody that binds only the activated form of α IIbβ 3 (Fig.  5a,b). We further examined the action of 
ADTM on the ERp57/α IIbβ 3 interaction by immunoprecipitation with anti-α IIbβ 3 antibody, followed 
by detection of ERp57 immunoreactivity using immunoblotting. It was found that ADTM disrupted the 
interaction of ERp57 with α IIbβ 3, both in the presence and absence of ADP (Fig. 5c).
ADTM increases vasodilator-stimulated phosphoprotein (VASP) phosphorylation and HO-1 
protein level. In platelets, the phosphorylation of VASP is involved in the down-regulation of platelet 
Figure 4. ADTM inhibited the expression of P-selectin. Whole blood was treated with DMSO (0.1%) as a 
control or the indicated concentrations of ADTM (1–100 μ M) for 5 min at 37 °C. After that the platelets were 
activated using ADP (10 μ M). Flow cytometry histogram (a) and the quantification of the data (b) show that 
ADTM inhibits P-selectin binding to ADP-activated platelets. #P < 0.01 compared with the control group, 
*P < 0.01 compared with the ADP group. Data are representative of three independent experiments.
Figure 5. ADTM inhibits activation of αIIbβ3 integrin and disrupts the ERp57/αIIbβ3 complex on 
platelets. Representative flow cytometry histogram (a) and the quantification of the data (b) show that 
ADTM inhibits PAC-1 binding to ADP-activated platelets. (c) ADTM disrupts the ERp57/α IIbβ 3 complex. 
Whole blood was treated with DMSO (0.1%) as a control or 100 μ M ADTM for 5 min at 37 °C. After that 
the platelets were activated using ADP (10 μ M). Platelet lysates were prepared for immunoprecipitation 
(IP) and probed with anti-ERp57 antibody for immunoblot analysis (IB). The precipitates were also blotted 
with anti-α IIbβ 3 antibody to ensure that equal amounts of α IIbβ 3 were pulled down under each condition. 
#P < 0.01 compared with the control group, *P < 0.01 compared with the ADP group. Data are representative 
of three independent experiments.
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aggregation accompanied by inhibition of platelet integrin α IIbβ 3 activation27,28. As shown in Fig.  6a, 
pretreatment with ADTM (10 and 100 μ M) stimulated approximately three-fold increase in the phospho-
rylation of VASP. In addition, we also observed that ADTM increased the protein expression of HO-1, 
an anti-oxidative stress microsomal enzyme which when up-regulated could inhibit platelet-dependent 
thrombus formation (Fig. 6b)29.
Inhibition of platelet aggregation and thrombus formation by ADTM in vivo. Various con-
centrations of ADTM were administered in rats in vivo (10 –20 mg/kg, 5 days, intravenous, IV) and 
the platelet aggregation activity and the thrombus formation were evaluated. As shown in Fig.  7, 
ADP-induced platelet aggregation was significantly compromised (> 40% reduction) in rats treated with 
ADTM (20 mg/kg). Similarly, ADTM also exhibited significant anti-thrombotic effect in vivo as shown 
in the ferric chloride (FeCl3)-induced venous thrombosis (Fig.  8a). The inhibitory effects of ADTM 
in platelet aggregation and thrombus formation were comparable to clopidogrel. Furthermore, FeCl3 
induced significant decrease in plasma 6-Keto-PGF1α (an indicator of plasma PGI2, an intrinsic inhibitor 
Figure 6. Effects of ADTM on VASP phosphorylation and HO-1 protein Level. Rat platelets (1 × 108 
platelets/ml) were incubated with DMSO and various concentrations of ADTM for 10 min followed 
by treatment with ADP for 5 min. Proteins were extracted from the rat platelets and then analyzed by 
immunoblot using antibodies against VASP and HO-1 as described in Materials and Methods. ADTM 
increased VASP phosphorylation (a) and HO-1 protein expression (b). *P < 0.05 compared with the ADP-
stimulated group.
Figure 7. ADTM inhibits platelet aggregation-induced by ADP in a concentration-dependent manner in 
vivo. In order to compare the activities of ADTM, DSS, TMP, DSS + TMP and clopidogrel at a similar blood 
concentration, 20 mg/kg of ADTM (MW: 444), 10 mg/kg of DSS (MW: 220) and 6 mg/kg of TMP (MW: 
136) alone and in combination, and 18 mg/kg of clopidogrel (MW: 322) were administered by IV injection 
once daily. This resulted in approximately the same blood concentration of ADTM, DSS, TMP, DSS + TMP 
and clopidogrel in rats in vivo. Five days after drug treatment, blood was withdrawn and ADP-induced 
platelet aggregation was measured. Data are expressed as mean ± SD, n ≥ 6/group. D = DSS, T = TMP, 
clop = clopidogrel, MW = molecular weight.
www.nature.com/scientificreports/
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of platelet aggregation) and the treatment of ADTM (20 mg/kg, 5 days, IV) abolished the reduction of 
FeCl3-induced 6-Keto-PGF1α in a concentration-dependent manner (Fig.  8b), giving more evidence of 
the anti-thrombotic properties of ADTM.
Discussion
Anti-thrombotic therapy plays an essential role in the course of treatment of various cardiovascular dis-
orders (CVDs) because platelet dysfunction and thrombogenesis are common underlying factors in the 
development and progression in CVDs, particularly atherosclerosis, myocardial infarction and ischemic 
stroke. Aspirin and clopidogrel are most routinely used anti-platelet agents for the management of CVDs, 
but these agents irreversibly inhibit platelet activation with potentially devastating unwanted effects such 
as hemorrhages. In present study we reported that ADTM, a novel cardioprotective compound synthe-
sized in our own laboratory6, displayed specific binding for several members of the PDI family. By using a 
biotin-conjugated ADTM analogue (BAA) as bait and chemical proteomic analysis of the bound protein 
complexes, we identified eight potential interacting protein targets of ADTM (Supplementary Table S1). 
With further validation using immunoblot analysis the identity of major targets were confirmed as mem-
bers of the PDI family, including ERp72, ERp57 and ERp5. In particular, ADTM showed highest potency 
in inhibiting the redox activity of ERp57 in enzymatic assay in vitro. Furthermore, untagged-ADTM 
could compete with BAA for the binding of ERp57, providing evidence that ADTM is a competitive 
ligand at ERp57. We further demonstrated that ADTM displayed concentration-dependent inhibition 
in ADP-induced platelet aggregation and AA-induced platelet aggregation in vitro. This result is in line 
with the observation that ERp57 has been recently implicated to play crucial roles in mediating platelet 
aggregation, homeostasis and thrombosis18–20. It has also been reported that ERp57 present on platelet 
surface were activated by staphylococcal extracellular adhesive protein resulting in arteriosclerosis in 
Staphylococcus aureus infection, and the inhibition of ERp57 could suppressed platelet aggregation30.
We further demonstrated that ADTM concentration-dependently inhibited the ADP-induced 
expression of P-selectin and activation of α IIbβ 3 integrin in vitro. P-selectin is an adhesion molecule 
expressed on the surface of platelet and is an important marker for platelet activation. α IIbβ 3 integrin 
is the most abundant adhesion receptor on the surface of circulating platelets and has been reported to 
Figure 8. Anti-thrombotic effect of ADTM in the FeCl3-induced rat thrombosis model. The anti-
thrombotic effect of ADTM in the FeCl3-induced inferior vena cava thrombosis model (a). In order to 
compare the activities of ADTM, DSS, TMP and clopidogrel at similar blood concentrations, the compounds 
were administered by IV injection as described in Fig. 7. The effect of ADTM on plasma 6-Keto-PGF1a 
concentration in the FeCl3-induced thrombosis model (b). Data are expressed as mean ± SD, #P < 0.01 
compared with the sham group, *P < 0.05 compared with the vehicle group, n = 5–7/group, D = DSS, 
T = TMP, clop = clopidogrel.
www.nature.com/scientificreports/
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mediate platelet aggregation through strong interactions with adhesive proteins such as fibrinogen, von 
Willebrand factor and fibronectin31. We further demonstrated that ERp57 bound to α IIbβ 3 directly by 
using co-immunoprecipitation, and ADTM disrupted ERp57/α IIbβ 3 interaction, as shown by the dis-
sociation of the complex (Fig. 5c). In line with this, ERp57 has been reported to directly interact with 
α IIbβ 3 on platelet surface and regulate its function in platelet aggregation18–20. Recent study has shown 
that disulfide bond exchanges in α IIbβ 3 is required for activation and post-ligation signaling during 
clot retraction32, and the modulation of functional disulfide bonds is being explored for blood protein 
control33. Our results suggested that ADTM produced its anti-thrombotic action via the modulation of 
disulfide bond by interacting with ERp57 (Fig. 9).
The inhibitory action of ADTM on platelet integrin α IIbβ 3 activation was furthered evidenced by 
the increase of the phosphorylation of VASP after ADTM pretreatment. The phosphorylation VASP is 
involved in the down-regulation of platelet aggregation accompanied by inhibition of platelet integrin 
α IIbβ 3 activation27,28. We also observed that ADTM increased the expression of HO-1 in platelets. This is 
coherent with our previous finding that HO-1 activation has a key role in ADTM cardioprotective effect 
in H9c2 cardiomyoblast cells in vitro and in the myocardium in vivo7. HO-1 is a potential therapeutic 
target in treating thrombotic disease and HO-1 knockout mice demonstrated acute thrombus formation 
in response to hypoxia34. Previous studies reported that dengue virus glycoprotein-1 (DV-NS1) anti-
body inhibited PDI activity and blocked platelet aggregation accompanied by an increase in HO-135,36. 
Furthermore, redox reactions have been shown to play crucial roles in platelet aggregation in a glu-
tathione peroxidase-3 (GPx-3)-deficient mouse model. GPx-3 is an important anti-oxidant enzyme and 
redox sensor in plasma and GPx-3-deficiency impaired normal platelet inhibition and promoted throm-
bosis due to enhanced reactive oxygen species flux and decreased nitric oxide bioavailability37. In our in 
vivo studies, we observed that ADP-induced platelet aggregation was significantly compromised (> 40% 
reduction) in rats treated with ADTM (20 mg/kg). The anti-thrombotic effect of ADTM was further evi-
denced by the reduction of platelet activity and thrombus formation in the ferric chloride (FeCl3)-induced 
venous thrombosis assay in the rat. The major metabolites of ADTM in vivo were 2-hydroxymethy-3, 
5, 6-trimethylpyrazin (TMP-OH) and DSS38. We have checked the in vivo activity of DSS and TMP. 
Interestingly, the results showed that ADTM exhibited stronger antiplatelet and anti-thrombotic activities 
when compared to DSS and TMP, alone or in combination in ADP-induced platelet aggregation and 
FeCl3-ionduced thrombosis model, respectively (Figs.  7 and 8). The precise mechanisms of this action 
conferred by ADTM would be another interesting question that is worth investigating in the future. 
Recently there are accumulating reports that the inhibition of protein disulfide isomerases including 
PDI and ERp57 could block thrombus formation in various in vivo models and suggest that this protein 
family represents an important novel class of anti-thrombotic target39–43. Preclinical studies demonstrate 
that deficiency in platelet ERp57 resulted in the increased tail bleeding times and delayed thrombus 
formation20, while PDI is unable to compensate for the absence of platelet ERp5720 and other study also 
showed that the blockade of ERp57 with specific antibody further inhibited platelet aggregation in PDI 
deficient platelets16. These independent studies further provided evidences that ERp57 and PDI have 
distinct roles in the mediation of platelet function.
Taken together, our present study reported the anti-thrombotic action of ADTM with both in vitro 
and in vivo data. ADTM exhibited comparable anti-thrombotic properties as aspirin and clopidogrel. 
The results suggested that the anti-thrombotic action of ADTM is mediated through disrupting the 
Figure 9. Proposed mechanism of ADTM anti-platelet aggregation. In part, ADTM binds with ERp57 
and inhibits its redox activity, inhibits the activation of α IIbβ 3 and the expression of P-selection and 
enhances the expression of HO-1 and phosphorylation of VASP. The crosstalk between ERp57 and α IIbβ 3 
is involved in the biological action of ADTM. In addition, ADTM reverses the decreased level of 6-Keto-
PGF1α , a stable metabolite of PGI2 in the FeCl3-induced thrombosis model in vivo.
www.nature.com/scientificreports/
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interaction between ERp57 and α IIbβ 3 possibly by blocking the action of ERp57 on disulfide bonding 
(Fig. 9). Our data provided a rationale for the further development of ADTM as anti-thrombotic agent 
targeting the underlying mechanism involving ERp57 and α IIbβ 3. Furthermore, as a competitive ligand 
at ERp57, ADTM presents as a promising compound for the development of versatile anti-thrombotic 
agents. Our data also provide insights in novel strategies for the development of drugs targeted ERp57 
for anti-thrombotic.
Methods
Materials. ADTM and BAA were synthesized at Jinan University, China. DSS and TMP were of analyti-
cal pure grade, and obtained from Xi’an Honson Biotechnology (China) and Shanghai Banghai Chemical 
Company (China), respectively. Human recombinant ERp57 was obtained from Abcam (Cambridge, 
UK), PDI and ERp72 were purchased from Enzo Life Sciences (Exeter, UK). Insulin, DTT, AA and ADP 
were obtained from Sigma Aldrich (St. Louis, MO, USA).
Preparation of platelet-rich plasma. All animal experiments were approved by the Animal Care and 
Experimentation Committee of Jinan University and were performed in accordance with the approved 
guidelines. Sprague-Dawley rats were anesthetized with 10% chloral hydrate, and blood was obtained 
by an arterial puncture. Whole blood was anticoagulated with citrate (3.8%; 1:9, v/v) and centrifuged at 
200 g for 8 min at room temperature to obtain platelet-rich plasma (PRP). The residue was centrifuged 
at 550 g for 5 min to obtain platelet-poor plasma (PPP).
Protein preparation from platelets. Washed platelets were lysed using a dounce homogenizer in 
NP-40 lysis buffer (Beyotine, China) with 1 mM phenylmethylsulfonyl fluoride (PMSF). Platelet lysates 
were centrifuged at 12,500 g for 20 min at 4 °C, and the supernatant was collected and stored at − 80 °C 
until further analysis.
NeutrAvidin Agarose Resin pull-down with BAA. Platelet lysates (3 μ g/μ l) were exposed to 
NeutrAvidin Agarose Resin (Pierce Biotech., Rockford, IL, USA) for 2 h at 4 °C and then centrifuged for 
3 min at 2,500 g. The resin was discarded to remove endogenous biotin. Aliquots of supernatants (300 μ l) 
were first treated with DMSO or ADTM (600 μ M) for 2 h, and then incubated with BAA (600 μ M) for 
another 2 h. The supernatant was combined with NeutrAvidin Agarose Resin and allowed to shake over-
night at 4 °C as described previously44. To eliminate the nonspecific combination with compound or aga-
rose resin before protein analysis, 0.1% DMSO was added to one aliquot of lysate as a negative control.
Nano LC-MS/MS analysis. The compound-protein complex bound to agarose resin was digested with 
trypsin. The digested peptides were analyzed with 1D nano-RP LC-MS/MS. Acquired MS data were ana-
lyzed using the Paragon algorithm in ProteinPilot 4.0 software (Applied Biosystems, Framingham, MA, 
USA). The identified peptides from the Paragon algorithm were grouped into minimal non-redundant 
protein sets by the ProGroup algorithm of the software (details of this method can be found in 
Supplementary Methods).
Immunoblot analysis. Proteins eluted from the resin were subjected to SDS-PAGE and then trans-
ferred to a PVDF membrane for immunoblot (details in Supplementary Methods).
Insulin reduction assay. PDI activity was measured using an assay that measured the catalytic 
reduction of insulin, as described previously with minor modifications39,45. Briefly, insulin (1 mg/ml) was 
freshly prepared in assay buffer (100 mM potassium phosphate, 1 mM EDTA (pH 7.4) and 10 μ M dithi-
othreitol). 50 μ l of insulin was incubated in the presence of 10 μ l of enzyme and varying concentrations 
of compound, and then 10 μ l of 0.1 mM dithiothreitol was added. The increase in turbidity was moni-
tored at 620 nm using a microplate reader (Perkin-Elmer, Singapore) at 25 °C for 60 min. PDI, ERp57, 
and ERp72 were all used at 0.04 mg/ml. PDI family enzyme inhibition in the presence of compound 
was determined by the following formula: enzyme inhibition (%) = [1–(OD[compound + PDI + DTT]–OD[DTT])/
(OD[PDI + DTT]–OD[DTT])] × 100%.
Platelet aggregation in vitro. The inhibitory effect of ADTM was examined as previously described 
with modifications39. Briefly, platelets were incubated with the indicated concentrations of compounds or 
0.1% DMSO at 37 °C for 5 min with shaking. Aggregation was induced by ADP (10 μ M) or AA (200 μ M) 
and measured using a platelet aggregometer (SC-2000, Saikexide Instrument Co. Ltd. China). Inhibition 
of aggregation was calculated using the following general formula: inhibition of aggregation = (rate of 
aggregation in vehicle group – rate of aggregation in treated group)/rate of platelet aggregation in vehicle 
group × 100%.
Determination of human platelet activation by flow cytometry. Flow cytometry and immuno-
precipitation studies involving human platelets were approved by Jinan University with informed consent 
in accordance with the World Medical Association Declaration of Helsinki and carried out in accord-
ance with the approved guidelines. Flow cytometry was performed as described in the Supplementary 
www.nature.com/scientificreports/
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Methods. PE conjugated anti-CD62P (P-selectin) antibody and FITC conjugated anti-PAC-1 (activated 
α IIbβ 3) antibody were used to detect platelet activation markers after exposure to ADP in the presence 
of DMSO (0.1%) or different concentrations of ADTM. An isotype-matched IgG1 PE/FITC was used as 
a negative control.
Immunoprecipitation. To determine ERp57-bound α IIbβ 3 contents, whole platelet lysates were 
incubated with anti-α IIbβ 3 antibody overnight at 4 °C under agitation. The antigen-antibody complex 
was pulled down after incubation for 4 h at 4 °C with protein G-agarose (Cell Signaling Technology) as 
described previously46. Immune complexes were boiled for 5 min with 2 × loading buffer followed by 
immunoblot analysis with antibodies for ERp57 and α IIbβ 3.
Rat platelet aggregation-induced by ADP in vivo. To study the effects of ADTM on platelet 
aggregation in vivo, ADTM (5–20 mg/kg) in comparison with DSS (10 mg/kg), TMP (6 mg/kg), DSS 
(10 mg/kg) + TMP (6 mg/kg) and clopidogrel (18 mg/kg) were administered daily by IV injection for 5 
days, respectively (detailed methodology in Supplementary Methods). Platelet aggregation was moni-
tored for 5 min and the maximum aggregation inhibition (%) was calculated.
FeCl3-induced inferior vena cava thrombosis in rat. Rats weighing 180 g to 220 g were anesthe-
tized by intraperitoneal administration of 10% chloral hydrate. One hour post-treatment, the medioven-
tral line in the rats was cut and the inferior vena cava was surgically exposed by blunt dissection. 1 × 1 cm 
filter paper, soaked in 50% FeCl3 solution, was placed under and above the exposed inferior vena cava for 
15 min. Subsequently, the thrombosed inferior vena cava was carefully dissected, and the weight (mg) of 
wet thrombus harvested from the inferior vena cava was measured as described previously47.
Evaluation of plasma 6-Keto-PGF1α levels in rat. The concentration of 6-keto-PGF1α present in 
the supernatant was measured using a radioimmunoassay kit (New England Nuclear Dupont, Boston, 
MA) according to the manufacturer’s instructions. Blood was collected into plastic tubes containing 10% 
EDTA-Na2. Plasma was prepared by centrifuging blood at 550 g for 10 min. Plasma concentrations of 
6-keto-PGF1α were determined by radioimmunoassay and expressed as pg/ml.
Statistical analysis. All assays were performed at least three times. Data are presented as mean ± SD. 
The groups were compared using one-way ANOVA followed by Tukey’s multiple comparison tests using 
the statistics module of Graph Pad Prism 5.0. A value of P < 0.05 was considered statistically significant.
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In this Article, Fig. 5 is a duplication of Fig. 7. The correct Fig. 5 appears below as Fig. 1.
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